Literature DB >> 12824969

Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study.

Richard Guido1, Mark Schiffman, Diane Solomon, Louis Burke.   

Abstract

OBJECTIVE: This study was undertaken to compare postcolposcopy management strategies for women referred for low-grade squamous intraepithelial lesions (LSIL) or oncogenic human papillomavirus (HPV) DNA-positive atypical squamous cells of undetermined significance (ASCUS), with cervical intraepithelial neoplasia (CIN) grade 1 or less found at initial colposcopy. STUDY
DESIGN: A 2-year prospective follow-up of 1539 women was designed to assess the percentage sensitivity of different postcolposcopy management strategies to detect subsequent CIN grade 2 or 3 and percentage referral to repeat colposcopy.
RESULTS: HPV testing at 12 months was sensitive (92.2%) for detection of CIN grade 2 or 3 with a referral rate to repeat colposcopy of 55.0%. Repeat semiannual cytology with referral to colposcopy at an ASCUS threshold demonstrated similar sensitivity (88.0%) but with a higher rate of referral to colposcopy (63.6%). Combining cytology and HPV testing did not increase sensitivity and hurt specificity. Baseline viral load and colposcopic impression were not helpful.
CONCLUSION: The most efficient test for identifying women with CIN grade 2 or 3 after colposcopy might be an HPV test alone at 12 months.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824969     DOI: 10.1067/mob.2003.456

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  23 in total

1.  When to test women for human papillomavirus.

Authors:  Mark Schiffman; Philip E Castle
Journal:  BMJ       Date:  2006-01-14

2.  Detection of carcinogenic human papillomavirus in specimens collected with a novel self-sampling device.

Authors:  Philip E Castle; Asma Aftab; Gilbert Saint-Jean; Luis Mendez
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 3.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

4.  Quantitative physiology of the precancerous cervix in vivo through optical spectroscopy.

Authors:  Vivide Tuan-Chyan Chang; Peter S Cartwright; Sarah M Bean; Greg M Palmer; Rex C Bentley; Nirmala Ramanujam
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

5.  Risk factors for persistent cervical intraepithelial neoplasia grades 1 and 2: managed by watchful waiting.

Authors:  Gloria Y F Ho; Mark H Einstein; Seymour L Romney; Anna S Kadish; Maria Abadi; Magdy Mikhail; Jayasri Basu; Benjamin Thysen; Laura Reimers; Prabhudas R Palan; Shelly Trim; Nafisseh Soroudi; Robert D Burk
Journal:  J Low Genit Tract Dis       Date:  2011-10       Impact factor: 1.925

6.  Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer.

Authors:  Philip E Castle; Ana C Rodríguez; Robert D Burk; Rolando Herrero; Allan Hildesheim; Diane Solomon; Mark E Sherman; Jose Jeronimo; Mario Alfaro; Jorge Morales; Diego Guillén; Martha L Hutchinson; Sholom Wacholder; Mark Schiffman
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

7.  Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.

Authors:  Carolina Porras; Nicolas Wentzensen; Ana C Rodríguez; Jorge Morales; Robert D Burk; Mario Alfaro; Martha Hutchinson; Rolando Herrero; Allan Hildesheim; Mark E Sherman; Sholom Wacholder; Diane Solomon; Mark Schiffman
Journal:  Int J Cancer       Date:  2011-08-02       Impact factor: 7.396

8.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

9.  Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.

Authors:  Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

10.  Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections.

Authors:  Philip E Castle; Aimée R Kreimer; Sholom Wacholder; Cosette M Wheeler; Laura A Koutsky; Greg Rydzak; Dennis W Buckman; Barry Graubard; Mark Schiffman
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.